Ming De Yu
Président chez Chinese Pharmaceutical Enterprises Association
Profil
Ming De Yu is currently the Chairman of the Chinese Pharmaceutical Enterprises Association and the Chairman of the China Medical Entrepreneur Association.
He previously served as the Honorary Chairman of Beijing Pharmaceutical Group Co., Ltd.
from 2004 to 2010.
He also held positions as an Independent Director at 3SBio, Inc., China Nuokang Bio-Pharmaceutical, Inc., and North China Pharmaceutical Co., Ltd.
Additionally, he served as a Director at Sichuan Kelun Pharmaceutical Co., Ltd.
and as an Independent Director at Shandong Wohua Pharmaceutical Co., Ltd.
from 2012 to 2016.
Mr. Yu started his career as the Chief Technology Officer & Head-Manufacturing at Liaoning Fuxin Pharmaceutical Co. and Fuxin Traditional Chinese Medicine Co. from 1978 to 1983.
He obtained his undergraduate degree from Dalian University of Technology.
Currently, Mr. Yu is still serving as the Chairman of the Chinese Pharmaceutical Enterprises Association and the Chairman of the China Medical Entrepreneur Association.
Postes actifs de Ming De Yu
| Sociétés | Poste | Début |
|---|---|---|
| Chinese Pharmaceutical Enterprises Association | Président | 01/01/2004 |
| China Medical Entrepreneur Association | Président | - |
Anciens postes connus de Ming De Yu
| Sociétés | Poste | Fin |
|---|---|---|
| SHANDONG WOHUA PHARMACEUTICAL CO., LTD. | Directeur/Membre du Conseil | 06/01/2016 |
China Nuokang Bio-Pharmaceutical, Inc.
 China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | Directeur/Membre du Conseil | 01/01/2013 |
| NORTH CHINA PHARMACEUTICAL COMPANY.LTD | Directeur/Membre du Conseil | 01/01/2012 |
| Fuxin Traditional Chinese Medicine Co. | Directeur Technique/Scientifique/R&D | 01/01/1983 |
| Liaoning Fuxin Pharmaceutical Co. | Directeur Technique/Scientifique/R&D | 01/01/1983 |
Formation de Ming De Yu
| Dalian University of Technology | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| 3SBIO INC. | Health Technology |
| NORTH CHINA PHARMACEUTICAL COMPANY.LTD | Health Technology |
| SICHUAN KELUN PHARMACEUTICAL CO., LTD. | Health Technology |
| SHANDONG WOHUA PHARMACEUTICAL CO., LTD. | Health Technology |
| Entreprise privées | 6 |
|---|---|
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | Health Technology |
Beijing Pharmaceutical Group Co., Ltd.
 Beijing Pharmaceutical Group Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Pharmaceutical Group Co., Ltd. engages in the sale of Chinese medicines, chemical raw materials, chemical agents, antibiotics, biochemical drugs, and medical equipment. The company was found on March 28, 1987 and is headquartered in Beijing, China. | Health Technology |
| Chinese Pharmaceutical Enterprises Association | |
| China Medical Entrepreneur Association | |
| Liaoning Fuxin Pharmaceutical Co. | |
| Fuxin Traditional Chinese Medicine Co. |
